Arbutus Biopharma/$ABUS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Arbutus Biopharma
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Ticker
$ABUS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
44
Website
ABUS Metrics
BasicAdvanced
$626M
-
-$0.41
1.50
-
Price and volume
Market cap
$626M
Beta
1.5
52-week high
$3.73
52-week low
$2.71
Average daily volume
828K
Financial strength
Current ratio
6.011
Quick ratio
5.871
Long term debt to equity
6.361
Total debt to equity
7.072
Interest coverage (TTM)
-558.17%
Profitability
EBITDA (TTM)
-66.183
Gross margin (TTM)
-643.29%
Net profit margin (TTM)
-1,195.86%
Operating margin (TTM)
-1,054.79%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
-31.58%
Return on equity (TTM)
-79.02%
Valuation
Price to revenue (TTM)
96.717
Price to book
7.91
Price to tangible book (TTM)
7.91
Price to free cash flow (TTM)
-10.473
Free cash flow yield (TTM)
-9.55%
Free cash flow per share (TTM)
-0.312
Growth
Revenue change (TTM)
-50.69%
Earnings per share change (TTM)
-7.37%
3-year revenue growth (CAGR)
-33.17%
10-year revenue growth (CAGR)
-8.29%
3-year earnings per share growth (CAGR)
-16.68%
10-year earnings per share growth (CAGR)
-11.35%
Bulls say / Bears say
Arbutus Biopharma's imdusiran combination therapy has achieved functional cure in 8 chronic hepatitis B patients, demonstrating significant clinical progress. (arbutusbio.com)
The company has a strong cash position of approximately $123 million as of December 31, 2024, providing a solid financial foundation for ongoing research and development. (arbutusbio.com)
Arbutus has initiated international patent infringement lawsuits against Moderna, seeking monetary damages and injunctions, which could lead to significant financial gains if successful. (globenewswire.com)
The company reported a net loss of $24.5 million for Q1 2025, indicating ongoing financial challenges. (arbutusbio.com)
Arbutus underwent significant restructuring, including a 40% workforce reduction, which may impact operational efficiency and morale. (arbutusbio.com)
The company faces uncertainty in its hepatitis B program direction due to ongoing pipeline reviews, creating potential delays in development timelines. (panabee.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Arbutus Biopharma stock?
Arbutus Biopharma (ABUS) has a market cap of $626M as of August 04, 2025.
What is the P/E ratio for Arbutus Biopharma stock?
The price to earnings (P/E) ratio for Arbutus Biopharma (ABUS) stock is 0 as of August 04, 2025.
Does Arbutus Biopharma stock pay dividends?
No, Arbutus Biopharma (ABUS) stock does not pay dividends to its shareholders as of August 04, 2025.
When is the next Arbutus Biopharma dividend payment date?
Arbutus Biopharma (ABUS) stock does not pay dividends to its shareholders.
What is the beta indicator for Arbutus Biopharma?
Arbutus Biopharma (ABUS) has a beta rating of 1.5. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.